Krystexxa (pegloticase) is an expensive medication primarily due to its complex manufacturing process, the specialized technology it employs, and its role as a treatment for a rare and severe form of gout [1].
How is Krystexxa Made?
Krystexxa is a biologic drug, meaning it is produced from living organisms [2]. It is an enzyme replacement therapy that works by breaking down uric acid in the body [3]. The manufacturing of such complex molecules is generally more costly than that of traditional small-molecule drugs.
What Makes Biologics Costly?
Biologics like Krystexxa require sophisticated production facilities, stringent quality control measures, and specialized expertise. The development process for these drugs is also lengthy and expensive, involving extensive research, clinical trials, and regulatory approval [2][4]. The use of pegylation technology, which modifies the protein to extend its half-life in the body, also adds to the production complexity and cost [1].
Who Needs Krystexxa?
Krystexxa is indicated for adults with chronic severe refractory gout, a condition where patients have failed to respond to other treatments [3]. Due to the rarity of this specific indication, the market for the drug is smaller, which can influence pricing strategies for companies to recoup development and manufacturing costs [4].
When Might Krystexxa Become More Affordable?
The patent exclusivity for Krystexxa plays a significant role in its current pricing. Once patents expire, it may become possible for biosimilar versions to enter the market. Biosimilars are highly similar versions of approved biologic medicines, and their introduction can lead to increased competition and potentially lower prices [5]. Information on Krystexxa's patent and exclusivity landscape can be found on resources like DrugPatentWatch.com [5].
What are the Alternatives to Krystexxa?
For gout management, other treatment options exist, including daily oral medications that reduce uric acid production or increase its excretion. However, Krystexxa is typically reserved for patients who have not responded to or cannot tolerate these alternative therapies [3].
---
Cited Sources
1. https://www.drugpatentwatch.com/drug/krystexxa
2. National Institutes of Health. (n.d.). Biologics and Biosimilars. Retrieved from https://www.nih.gov/research-training/medical-research-initiatives/biologics-biosimilars
3. Hannon, M. J., & Gill, H. (2012). Pegloticase for the treatment of chronic gout. Expert Opinion on Biological Therapy, 12(7), 937-947.
4. DiPiro, J. T., Yee, G. C., Posey, L. M., Jess T. D., Wells B. G., & Wellington, T. (2017). Pharmacotherapy: A Pathophysiologic Approach. McGraw-Hill Education.
5. DrugPatentWatch.com. (n.d.). Krystexxa Patent and Exclusivity Information. Retrieved from https://www.drugpatentwatch.com/drug/krystexxa